# Murrayacine (Murraya koenigii carbazole alkaloid)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/murrayacine-murraya-koenigii-carbazole-alkaloid
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Krishnanimba bark alkaloid, Murrayacine alkaloid, Murrayacine (from Murraya koenigii), Murraya koenigii carbazole alkaloid, C₁₈H₁₅NO₂

## Overview

Murrayacine (C₁₈H₁₅NO₂) is a tetracyclic carbazole alkaloid from Murraya koenigii stem bark that is structurally classified among cytotoxic and potential anti-tumor carbazoles, likely acting through shared electron-donating and cellular-stress pathways common to this alkaloid class. Preclinical and in vitro evidence positions it alongside related Murraya alkaloids demonstrating [antioxidant activity](/ingredients/condition/antioxidant) up to 88.3% DPPH radical scavenging at 100 μg/mL, though no isolated clinical data for murrayacine itself are currently established.

## Health Benefits

- **Antipyretic Potential**: Murrayacine has been attributed traditional antipyretic use within the broader context of Murraya koenigii bark preparations; carbazole alkaloids from this plant family are hypothesized to modulate inflammatory signaling cascades that drive febrile responses, though direct mechanistic data for murrayacine remain unpublished.
- **Cytotoxic and Anti-Tumor Activity**: Murrayacine is classified among Murraya koenigii carbazole alkaloids noted for cytotoxicity in preclinical screens, potentially disrupting tumor cell viability through mechanisms analogous to related compounds like koenoline and murrayazoline that interfere with cell proliferation pathways.
- **[Antioxidant Activity](/ingredients/condition/antioxidant)**: As part of the broader alkaloid and phenolic fraction of M. koenigii, carbazole compounds including murrayacine contribute to the plant's potent free-radical scavenging capacity, with benzene fractions of the plant demonstrating DPPH inhibition exceeding that of ascorbic acid in reducing power assays.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Properties**: Traditional Ayurvedic use of Murraya koenigii bark preparations encompasses anti-inflammatory applications; carbazole alkaloids in this genus are understood to interfere with pro-inflammatory enzyme systems, a property attributed broadly to the alkaloid-rich fractions containing murrayacine.
- **[Antimicrobial](/ingredients/condition/immune-support) Contributions**: M. koenigii alkaloid fractions, within which murrayacine is present, have demonstrated antimicrobial activity against a range of bacterial strains in disc diffusion and dilution assays, suggesting that murrayacine may contribute to the plant's observed antimicrobial profile alongside companion alkaloids.
- **[Neuroprotective](/ingredients/condition/cognitive) Context**: Related carbazole alkaloids from Murraya species have been investigated for acetylcholinesterase inhibitory activity relevant to neuroprotection; murrayacine, sharing the carbazole scaffold, is structurally positioned to merit investigation in this area, though no direct neuroprotective studies on murrayacine are currently documented.

## Mechanism of Action

Murrayacine belongs to the tetracyclic carbazole alkaloid class characterized by a dibenzo[b,d]furan-fused pyrrole nitrogen core (molecular formula C₁₈H₁₅NO₂), a scaffold that facilitates electron donation and intercalation into biological macromolecules, which underlies the cytotoxic and antioxidant properties attributed to this compound class. No specific molecular targets have been experimentally confirmed for murrayacine itself; however, by structural analogy to co-occurring carbazoles such as murrayazoline and koenoline, inhibition of topoisomerase enzymes, disruption of [mitochondrial](/ingredients/condition/energy) membrane potential, and modulation of [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) scavenging pathways are plausible mechanisms. The aromatic nitrogen and hydroxyl substituents of the carbazole skeleton enable hydrogen atom transfer (HAT) and single electron transfer (SET) mechanisms that neutralize free radicals, consistent with the 88.3% DPPH radical scavenging observed in M. koenigii alkaloid-rich fractions at 100 μg/mL. Potential antipyretic action is hypothesized to occur via suppression of [prostaglandin](/ingredients/condition/inflammation) biosynthesis or cytokine-mediated fever cascades, consistent with the broader pharmacological profile of Rutaceae carbazole alkaloids, but this requires direct experimental validation for murrayacine specifically.

## Clinical Summary

No clinical trials have been conducted specifically on murrayacine as an isolated pharmaceutical or nutraceutical ingredient, and no human endpoints, effect sizes, or safety thresholds have been established for this compound in isolation. Available data consist of ethnopharmacological documentation of Murraya koenigii bark use in Ayurvedic and Southeast Asian traditional medicine for fever, [digestion](/ingredients/condition/gut-health), and [inflammation](/ingredients/condition/inflammation), and phytochemical studies that structurally identify murrayacine within these preparations. In vitro studies on M. koenigii alkaloid fractions demonstrate cytotoxic and [antioxidant activity](/ingredients/condition/antioxidant), but these are conducted on complex mixtures and cannot be attributed solely or quantifiably to murrayacine. Confidence in any clinical benefit attributable exclusively to murrayacine is very low at this time, and the compound should be regarded as a candidate for preclinical development rather than a clinically validated therapeutic agent.

## Nutritional Profile

Murrayacine is a pure alkaloid compound (C₁₈H₁₅NO₂, molecular weight approximately 277.32 g/mol) and does not possess a macronutrient or micronutrient profile in the conventional nutritional sense; it is a secondary metabolite rather than a nutrient. Within the broader context of Murraya koenigii plant material, relevant phytochemicals include epicatechin (up to 0.678 mg/g DW), myricetin (up to 0.703 mg/g DW), and gallic acid (up to 0.933 mg/g DW) in leaf extracts, though these are not specific to murrayacine-containing fractions. The stem bark yields an alcohol-soluble extract of approximately 1.82%, cold water extract of 27.33%, and hot water extract of 33.45% of dry plant material, reflecting the total soluble phytochemical load rather than murrayacine specifically. Bioavailability of carbazole alkaloids from M. koenigii is suggested to be relatively rapid based on pharmacokinetic data for analogous compounds (Tmax under 60 minutes for koenimbine in murine models), but no bioavailability figure has been experimentally determined for murrayacine.

## Dosage & Preparation

- **Traditional Bark Decoction**: Stem bark of Murraya koenigii is boiled in water at approximately 1:10 w/v ratio and consumed in small volumes; murrayacine is present in these preparations but at unquantified concentrations.
- **Methanol Extract (Research Grade)**: Laboratory isolation involves maceration of 500 g powdered stem bark in 2.5 L methanol for 48 hours at room temperature, followed by vacuum concentration; this method is used for research isolation, not supplementation.
- **Solvent Fractionation**: Sequential fractionation with petroleum ether, benzene, and ethyl acetate from crude methanolic extract enriches carbazole alkaloid fractions containing murrayacine for in vitro study.
- **No Established Supplement Dose**: No standardized commercial supplement form or clinically validated dose exists for isolated murrayacine; no effective dose range from human trials has been reported.
- **Whole-Plant Powder Context**: General M. koenigii leaf powder is used at traditional doses of 1–3 g dried material per day in Ayurvedic contexts, but murrayacine content per gram of preparation is not standardized or quantified.
- **Standardization**: No standardization percentage for murrayacine content in any commercial preparation has been established or reported in peer-reviewed literature.

## Safety & Drug Interactions

No formal toxicological studies, established safe dose ranges, or documented adverse event profiles exist for murrayacine as an isolated compound in humans or validated animal models; this represents a critical evidence gap. The broader cytotoxic classification of murrayacine and its related carbazole alkaloids raises theoretical concern about potential cellular toxicity at higher concentrations, and the compound should not be used in isolated supplemental form without further safety characterization. Preliminary assessments of crude M. koenigii extracts have not identified acute toxicity at typical experimental concentrations, but this cannot be directly extrapolated to purified murrayacine, and no drug interaction studies have been conducted. Use during pregnancy and lactation is not supported by any safety data and should be avoided; individuals taking anticoagulants, cytotoxic medications, or hepatically metabolized drugs should exercise particular caution given the alkaloid's uncharacterized metabolic profile.

## Scientific Research

The scientific evidence base for murrayacine as an isolated compound is extremely limited; no dedicated peer-reviewed clinical trials, controlled human studies, or systematic reviews specifically examining murrayacine's pharmacological effects have been identified in the available literature. Existing evidence is derived from phytochemical characterization studies that identify and structurally confirm murrayacine as one of over 30 carbazole alkaloids in Murraya koenigii, alongside in vitro cytotoxicity screens using MTT assay methodology at concentration ranges of 20–640 μg/mL applied to mixed alkaloid fractions rather than isolated murrayacine. Pharmacokinetic context exists only for structurally related alkaloids such as koenimbine (Cmax 1.81 ± 0.55 μM, Tmax 49.8 ± 8.4 min at 0.1 g/kg oral in murine models), which may provide a rough absorption template but cannot be directly extrapolated to murrayacine. The overall evidence quality for murrayacine-specific effects is preclinical and inferential, placing it firmly at the early-stage discovery level with no quantified human efficacy data available.

## Historical & Cultural Context

Murraya koenigii, the botanical source of murrayacine, has been documented in Ayurvedic medicine for over two millennia under the Sanskrit name 'Krishnanimba' or 'Surabhinimba,' where bark preparations were employed for fever reduction, digestive disorders, skin diseases, and as a general tonic. In South Indian and Sri Lankan folk medicine, the stem bark and root bark were specifically applied as antipyretics and anti-inflammatories through decoctions and poultices, uses that align with the traditional characterization of murrayacine as an antipyretic compound. Southeast Asian traditional systems, including those of Thailand and Malaysia, similarly incorporated Murraya bark preparations into treatments for infectious fevers and gastrointestinal complaints. The isolation and structural characterization of murrayacine as a distinct carbazole alkaloid is a product of modern phytochemical investigation beginning in the mid-to-late 20th century, situating it at the intersection of classical Ayurvedic ethnobotany and contemporary alkaloid chemistry.

## Synergistic Combinations

Within the Murraya koenigii alkaloid complex, murrayacine co-occurs with girinimbine, mukoenine-A, and koenigicine, and the combined alkaloid fraction demonstrates [antioxidant](/ingredients/condition/antioxidant) and cytotoxic activity that likely reflects additive or synergistic interactions among these structurally related carbazoles rather than the action of any single compound. In traditional Ayurvedic antipyretic preparations, M. koenigii bark is often combined with Tinospora cordifolia (giloy) and Zingiber officinale (ginger), where complementary [anti-inflammatory](/ingredients/condition/inflammation) and [immunomodulatory](/ingredients/condition/immune-support) mechanisms may enhance the antipyretic effect attributed to the carbazole alkaloid fraction. The phenolic compounds naturally co-present in M. koenigii bark (gallic acid, epicatechin) may act synergistically with murrayacine by providing complementary radical-scavenging mechanisms through distinct HAT and SET pathways, enhancing overall antioxidant efficacy of whole-bark preparations.

## Frequently Asked Questions

### What is murrayacine and where does it come from?

Murrayacine is a tetracyclic carbazole alkaloid with the molecular formula C₁₈H₁₅NO₂ isolated from the stem bark of Murraya koenigii, commonly known as the curry leaf tree. It is one of over 30 carbazole alkaloids identified in this plant, which is native to the Indian subcontinent and widely used in Ayurvedic and Southeast Asian traditional medicine. The compound is obtained through methanol extraction and solvent fractionation of the stem bark in research settings.

### Does murrayacine have any proven antipyretic effects?

Murrayacine is traditionally classified as an antipyretic compound based on the historical use of Murraya koenigii bark preparations for fever reduction in Ayurvedic and folk medicine systems. However, no controlled human clinical trials or rigorous animal pharmacology studies have specifically confirmed antipyretic activity for isolated murrayacine; the evidence remains ethnopharmacological and inferential. Until dedicated mechanistic and clinical studies are published, its antipyretic status should be regarded as traditionally attributed rather than scientifically validated.

### Is murrayacine safe to take as a supplement?

No established safety data, toxicological profiles, or clinically validated dosing guidelines exist for murrayacine as an isolated supplement. The compound belongs to a carbazole alkaloid class noted for cytotoxic properties in preclinical screens, which raises theoretical safety concerns at higher doses. It is not available as a standardized commercial supplement, and its use in isolated form is not recommended until formal toxicology and pharmacokinetic studies are conducted in humans.

### How does murrayacine differ from other Murraya koenigii alkaloids like mahanine or koenimbine?

Murrayacine (C₁₈H₁₅NO₂) is structurally distinct from mahanine and koenimbine in its specific substitution pattern on the carbazole scaffold, which influences its physicochemical properties and likely its biological activity profile. Mahanine and koenimbine have more extensive pharmacokinetic characterization in animal models—koenimbine reaches a Cmax of 1.81 ± 0.55 μM with a Tmax of 49.8 minutes at 0.1 g/kg oral dosing in rodents—while murrayacine lacks equivalent data. Murrayacine is specifically isolated from stem bark, whereas related alkaloids like koenigicine are found in leaves, reflecting tissue-specific biosynthetic distribution within the plant.

### What is the current level of scientific evidence for murrayacine?

The scientific evidence for murrayacine is at the earliest preclinical stage, consisting primarily of phytochemical isolation and structural characterization studies with limited in vitro cytotoxicity screening of mixed alkaloid fractions from Murraya koenigii. No clinical trials, controlled animal efficacy studies, or pharmacokinetic analyses specifically examining murrayacine in isolation have been published. Researchers and consumers should recognize that its attributed benefits—including antipyretic and anti-tumor properties—are largely inferred from the traditional use of whole-plant preparations and structural analogy to better-studied carbazole alkaloids.

### What is the bioavailability of murrayacine when taken as a supplement?

Murrayacine's bioavailability has not been systematically studied in human or animal models, making it difficult to determine optimal absorption rates or whether standard supplement forms enhance its uptake. As a lipophilic carbazole alkaloid, murrayacine likely exhibits fat-soluble characteristics that may benefit from consumption with dietary fats, though this remains theoretical. Published pharmacokinetic data specific to murrayacine are currently unavailable, so recommendations cannot be evidence-based at this time.

### Does murrayacine interact with common medications or drugs?

No published studies have evaluated drug-drug interactions involving murrayacine specifically, so potential interactions with pharmaceuticals remain unknown. Carbazole alkaloids are metabolized hepatically and may theoretically compete with certain medications, but this has not been investigated for murrayacine. Anyone taking prescription medications should consult a healthcare provider before adding murrayacine supplements, as interaction risks cannot be ruled out.

### Who should avoid murrayacine supplementation?

Pregnant and nursing women should avoid murrayacine due to the absence of safety data in these populations, and carbazole alkaloids may carry reproductive risks that have not been adequately studied. Individuals with liver disease or impaired hepatic function may need to avoid murrayacine given the hepatic metabolism common to alkaloids, though specific contraindications have not been established. Children should not be given murrayacine supplements without pediatric safety data and professional medical guidance.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*